News

Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week® 2025
Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated ...
Mallinckrodt To Present Data On TERLIVAZ® (Terlipressin) For Injection At The 2025 Digestive Disease Week (DDW) Annual Meeting
Five presentations highlight TERLIVAZ research in adults with HRS with rapid reduction in kidney function,1 also known as HRS-AKI<sup ...